NEW YORK (GenomeWeb News) – XDx said today that it has signed a pharmacogenomics pact with Bristol-Myers Squibb to identify biomarkers that would be used for diagnostic purposes in the development of a drug for systemic lupus erythematosus.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.